SCHEMBL24399726

SCHEMBL24399726

COc1ccc(CNc2nccc3c(C(=O)Nc4c(C)ccc5c(Nc6cccc(C(F)(F)F)c6)nccc45)cccc23)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 6/20 0.47
▸ MAPT P10636 4/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ KDR P35968 5/20 0.45
▸ BRAF P15056 4/20 0.44
▸ POLB P06746 3/20 0.44
▸ LCK P06239 2/20 0.44
▸ TEK Q02763 1/20 0.44
▸ GSK3A P49840 1/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ DDR1 Q08345 1/20 0.41
▸ DDR2 Q16832 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30400432 1.00 RAF1 (0.47) RAF1MAPTRXFP1KDRBRAF
SCHEMBL24399707 0.85 AURKA (0.47) RAF1MAPTBRAFPOLBCSF1R
SCHEMBL30401997 0.85 AURKA (0.47) RAF1MAPTBRAFPOLBCSF1R
SCHEMBL30401790 0.83 RAF1 (0.53) RAF1MAPTBRAFPOLBLMNA
SCHEMBL25378433 0.83 RAF1 (0.53) RAF1MAPTBRAFPOLBLMNA
SCHEMBL24399624 0.83 RAF1 (0.57) RAF1MAPTBRAFCSF1RDDR1
SCHEMBL30401720 0.83 RAF1 (0.57) RAF1MAPTBRAFCSF1RDDR1
SCHEMBL24399551 0.83 RAF1 (0.56) RAF1MAPTBRAFPOLBCSF1R
SCHEMBL30402799 0.83 RAF1 (0.56) RAF1MAPTBRAFPOLBCSF1R
SCHEMBL25376182 0.83 AURKA (0.54) RAF1MAPTBRAFPOLBCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
CN-116096718-A Aryl amide compound, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-05-09 — — CN disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM RAF1 2075/4885MAPT 2751/4885RXFP1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback